Preclinical Animal Models of MASLD and MASH: A Review of disease induction strategies
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major worldwide health concern, covering a wide range of conditions from basic hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advancing fibrosis, cirrhosis, and hepatocellular carcinoma. Growing disease burden alongside the scarcity of effective treatment options underscores the urgent need for dependable preclinical models are faithfully mimic the intricate metabolic and pathological aspects of a human condition. This review offers a thorough examination of animal models employed to study MASLD and MASH, focusing especially on their disease induction methods, pathological traits, metabolic characteristics, time required for disease development, and relevance to human translation. Dietary models such as High-fat diet, High-fat high-fructose diet, High-fat high-cholesterol diet, methionine and choline-deficient diet, choline-deficient L-amino acid defined diet, GAN diet, and ALIOS models recapitulate various stages of metabolic dysfunction and liver damage. Chemical models including streptozotocin, carbon tetrachloride, diethylnitrosamine, and thioacetamide prove valuable for hastening fibrosis and hepatocarcinogenesis. Genetically modified models like ob/ob, db/db, foz/foz, B6-Alms1-del, Ldlr−/−, and Apoe−/− mice shed light on the genetic and metabolic factors driving disease progression. Combination models merge dietary, chemical, and genetic strategies to more accurately reproduce advanced MASH and fibrosis. Emerging infection- and immunity-induced models further broaden opportunities to explore specific disease mechanisms. Overall, no single model completely mirrors human MASLD and MASH; thus, model selection ought to be directed by the particular research goal and disease stage being studied.
Authors
- Venu Talla (ORCID: https://orcid.org/0000-0002-4261-4225)
- Kompelli Bhanudeepika
- Bathula Jayasri
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24413494
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00